A novel DNA vaccine that delivers long lasting immunity by stimulating high avidity CD8 T cells and strong neutralising antibodies

一种新型 DNA 疫苗，通过刺激高亲和力 CD8 T 细胞和强中和抗体来提供持久的免疫力

• 批准号: 73437
• 金额: $ 311.4万
• 依托单位: SCANCELL LIMITED
• 依托单位国家: 英国
• 项目类别: Collaborative R&D
• 财政年份: 2020
• 资助国家: 英国
• 起止时间: 2020 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=73437
• 关键词: novel; DNA; vaccine; delivers; long

Scancell have developed a fast, low cost and effective DNA vaccine which stimulates potent immune responses that can kill cancer cells and has already been shown to be safe and effective in the treatment of patients with skin cancer. This approach can also be used to develop a safe and effective vaccine to prevent infection with viruses such as the coronavirus that causes COVID-19. Like other vaccines being developed, Scancell’s will help the body to make antibodies to stop the COVID-19 virus getting into cells and causing the person to become infected. What makes our vaccine different from other approaches is that it will also stimulate the immune system to make special T cells that can recognise and kill cells that may have been infected with the virus. These T cells will also remain in the body longer than antibodies and be there in case of future infections. Scancell has made two different vaccines: SCOV1 targets the original Wuhan strain of the virus and SCOV2 targets variant of concern, including Delta and Omicron. As all adults in the UK have now been offered a COVID-19 booster injection, the Scancell COVID-19 vaccines have been administered to healthy volunteers in South Africa where vaccination rates are much lower. Scancell’s vaccines are being given using a needle-free injection device which is easy to use, liked by patients and volunteers, and suitable for use in a pandemic. Evaluation of the safety profile and immune responses induced by the SCOV1 and SCOV2 vaccines in healthy volunteers will allow us to move into the next phase of the study in pre-vaccinated volunteers.

Scancell已经开发出一种快速、低成本和有效的DNA疫苗，这种疫苗可以刺激有效的免疫反应，杀死癌细胞，并且已经被证明在治疗皮肤癌患者方面是安全有效的。这种方法还可用于开发安全有效的疫苗，以预防感染导致COVID-19的冠状病毒等病毒。像其他正在开发的疫苗一样，Scancell的疫苗将帮助身体产生抗体，阻止COVID-19病毒进入细胞并导致人被感染。我们的疫苗与其他方法的不同之处在于，它还会刺激免疫系统产生特殊的T细胞，这些T细胞可以识别并杀死可能被病毒感染的细胞。这些T细胞也会比抗体在体内停留更长的时间，以防未来的感染。Scancell已经制造了两种不同的疫苗：SCOV1针对的是原武汉病毒株，而SCOV2针对的是关注的变种，包括Delta和Omicron。由于英国所有成年人现在都接受了COVID-19加强注射，Scancell COVID-19疫苗已被用于接种率低得多的南非的健康志愿者。Scancell的疫苗使用一种无针注射装置进行注射，这种装置易于使用，受到患者和志愿者的喜爱，并且适合在大流行期间使用。在健康志愿者中评估SCOV1和SCOV2疫苗的安全性和诱导的免疫反应，将使我们能够进入下一阶段的预接种志愿者研究。